Literature DB >> 10573228

Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis.

Y P Moodley1, R Chetty, U G Lalloo.   

Abstract

Cytokines such as tumour necrosis factor-alpha and interferon gamma are associated with active pulmonary inflammation in sarcoidosis and they upregulate inducible nitric oxide synthase (iNOS). The objectives of this study were to examine iNOS upregulation in sarcoidosis by showing raised exhaled nitric oxide and increased iNOS activity in lung biopsy specimens of these patients utilizing immunohistochemistry. Exhaled NO was measured by a chemiluminescence analyser in 12 patients with newly diagnosed biopsy-proven sarcoidosis before and after 6 weeks of corticosteroid therapy. Lung biopsy specimens from these patients were subjected to immunohistochemical staining with a specific iNOS antibody. Exhaled NO was raised in newly diagnosed sarcoidosis (mean+/-SEM): 9.8+/-0.4 versus 4.1+/-0.2 parts per billion (ppb) in 21 healthy controls, p<0.001; and fell significantly after 6 weeks treatment with corticosteroids to 5.9+/-1.4 ppb; p<0.01. There was no correlation between exhaled NO and other markers of disease activity. Immunohistochemical staining demonstrated iNOS activity in respiratory epithelium and granulomas in patients with sarcoidosis. Exhaled nitric oxide is raised in patients with active pulmonary sarcoidosis and may be a result of inducible nitric oxide synthase upregulation. The fall in exhaled nitric oxide following corticosteroid therapy may reflect inhibition of inducible nitric oxide synthase in the respiratory epithelium and granulomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573228     DOI: 10.1034/j.1399-3003.1999.14d17.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

2.  Exhaled nitric oxide in sarcoidosis.

Authors:  M L Wilsher; W Fergusson; D Milne; A U Wells
Journal:  Thorax       Date:  2005-10-21       Impact factor: 9.139

3.  Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: a pilot feasibility study.

Authors:  J Choi; L A Hoffman; J M Sethi; T G Zullo; K F Gibson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

Review 4.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses.

Authors:  Thomas J Gross; Karol Kremens; Linda S Powers; Brandi Brink; Tina Knutson; Frederick E Domann; Robert A Philibert; Mohammed M Milhem; Martha M Monick
Journal:  J Immunol       Date:  2014-01-29       Impact factor: 5.422

Review 6.  Breath tests in respiratory and critical care medicine: from research to practice in current perspectives.

Authors:  Attapon Cheepsattayakorn; Ruangrong Cheepsattayakorn
Journal:  Biomed Res Int       Date:  2013-09-18       Impact factor: 3.411

7.  Exhaled nitric oxide in diagnosis and management of respiratory diseases.

Authors:  Abdullah A Abba
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

Review 8.  Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments.

Authors:  Rashi Jain; Dhananjay Yadav; Nidhi Puranik; Randeep Guleria; Jun-O Jin
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

Review 9.  Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review.

Authors:  Paolo Cameli; Elena Bargagli; Laura Bergantini; Miriana d'Alessandro; Maria Pieroni; Giovanni A Fontana; Piersante Sestini; Rosa Metella Refini
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.